Spero Therapeutics stock (US85208T1079): Q1 2026 results and FDA catalyst in focus

Spero Therapeutics has reported its first-quarter 2026 results while partner GSK advances the tebipenem HBr NDA with an FDA decision expected in June 2026. Investors are weighing lower revenue against a major upcoming regulatory milestone for the anti-infectives developer.

Spero Therapeutics reported first-quarter 2026 financial results and provided a business update that highlighted lower revenue driven by reduced clinical activity, while confirming that the U.S. Food and Drug Administration is reviewing partner GSK’s New Drug Application for tebipenem HBr with a Prescription Drug User Fee Act decision date of June 18, 2026, according to a company press release published on May 13, 2026 and a Reuters report dated May 13, 2026.Business Insider as of 05/13/2026Reuters as of 05/13/2026

As of: 05/14/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: SPRO
• Sector/industry: Biopharmaceuticals / anti-infectives
• Headquarters/country: Cambridge, Massachusetts, United States
• Core markets: Anti-infective therapies for rare diseases and serious infections
• Key revenue drivers: Collaboration and milestone payments, R&D funding, potential future product sales
• Home exchange/listing venue: Nasdaq (ticker: SPRO)
• Trading currency: U.S. dollar (USD)

Spero Therapeutics: core business model

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and serious bacterial infections with high unmet medical need, particularly in the field of anti-infectives and multi-drug resistant pathogens, according to the company’s description in its first-quarter 2026 update.Business Insider as of 05/13/2026

The company’s strategy relies on partnering with larger pharmaceutical groups to share development, regulatory and commercialization responsibilities, illustrated by its collaboration with GSK on tebipenem HBr, an oral carbapenem antibiotic being developed for complicated urinary tract infections including pyelonephritis.StockTitan as of 02/20/2026

Spero’s pipeline and portfolio include product candidates aimed at providing oral or otherwise more convenient treatment alternatives to existing intravenous therapies, a positioning that seeks to address hospital resource constraints and patient quality-of-life concerns in infections that currently rely heavily on inpatient IV regimens, according to the company’s business update.Business Insider as of 05/13/2026

Main revenue and product drivers for Spero Therapeutics

In the first quarter of 2026, Spero’s revenue declined compared with the prior-year period, which the company and Reuters attributed primarily to decreased clinical activity and related revenue recognition, underscoring the firm’s reliance on milestones and collaboration funding rather than recurring product sales at this stage.Reuters as of 05/13/2026

A key revenue driver in 2026 is expected to be milestone income linked to the progress of tebipenem HBr, including a previously disclosed $25 million milestone payment triggered by GSK’s resubmission of the tebipenem HBr NDA to the FDA in December 2025, which Spero has indicated it expects to recognize in early 2026 depending on contractual terms and timing.StockTitan as of 12/19/2025

Tebipenem HBr itself is designed as an oral carbapenem antibiotic intended to provide an effective alternative to intravenous carbapenems for complicated urinary tract infections, including pyelonephritis, a profile that could expand treatment options beyond hospital settings if the product secures regulatory approval and reimbursement, according to the company and GSK’s development plans.Business Insider as of 05/13/2026

Spero and GSK have highlighted results from the Phase 3 PIVOT-PO trial, which was stopped early for efficacy in May 2025 and later presented in October 2025, and those data supported GSK’s NDA submission in December 2025, forming the core clinical evidence package currently under FDA review for tebipenem HBr.StockTitan as of 10/20/2025

Q1 2026 results and financial position

For the first quarter of 2026, Spero reported lower revenue compared with the same period a year earlier, reflecting decreased clinical activity, while continuing to invest in its pipeline and maintain a cash position intended to support operations through upcoming regulatory milestones, according to the company’s earnings release and a Reuters summary.Business Insider as of 05/13/2026Reuters as of 05/13/2026

The company’s first-quarter update also reiterated that the NDA for tebipenem HBr is under active FDA review, with Spero emphasizing the potential importance of this program for its long-term revenue expectations and for the value of its broader anti-infective franchise if the therapy gains approval and successful market uptake, according to the same press release.Business Insider as of 05/13/2026

While detailed cash figures were not disclosed in secondary summaries, Spero’s emphasis on its collaboration structure and milestone potential suggests that management is seeking to extend the company’s financial runway by leveraging partner funding and carefully pacing its own internal R&D spending in the near term, based on the discussion in its business update.Business Insider as of 05/13/2026

Regulatory milestones: tebipenem HBr and the June 2026 FDA decision

A central near-term catalyst for Spero is the FDA’s review of the tebipenem HBr NDA, which GSK resubmitted on December 19, 2025 and which is now associated with a PDUFA decision date of June 18, 2026, according to company commentary and partner disclosures cited in recent news coverage.StockTitan as of 12/19/2025Business Insider as of 05/13/2026

The NDA submission is backed by data from the Phase 3 PIVOT-PO trial, which demonstrated non-inferiority of oral tebipenem HBr compared with intravenous imipenem-cilastatin in complicated urinary tract infections, with reported overall success rates of 58.5% versus 60.2% and an adjusted difference of 1.3% within the pre-specified confidence interval, according to summaries of the trial results.StockTitan as of 10/20/2025

GSK holds exclusive commercialization rights to tebipenem HBr outside certain Asian territories where Meiji retains rights, while Spero is positioned to receive milestone payments and potential royalties, creating a leveraged exposure to the commercial outcome of the program without Spero bearing full global commercialization costs, based on the terms outlined in company updates and partner statements.StockTitan as of 12/19/2025

The upcoming June 2026 PDUFA date therefore represents a key binary event for Spero’s medium-term outlook, as a positive regulatory decision could unlock additional milestones and position tebipenem HBr for a potential U.S. launch, whereas a delay or negative outcome would likely prompt reassessment of timelines and strategy, according to the way management framed the opportunity in its first-quarter communication.Business Insider as of 05/13/2026

Stock performance context and volatility

Following the release of its first-quarter 2026 results and business update, Spero Therapeutics shares have shown volatility typical of small-cap biotech stocks, with short-term price moves influenced by shifting expectations around the FDA decision timeline and perceptions of the company’s funding runway, according to market data summaries from U.S. trading platforms as of mid-May 2026.StockInvest.us as of 05/13/2026

On May 13, 2026, one trading data provider reported that Spero’s stock fell by around 3.9% to approximately $2.44 after a series of declines over several days, illustrating how incremental news flow and changing risk appetite can translate into meaningful percentage swings for lower-priced biotech names on Nasdaq.StockInvest.us as of 05/13/2026

For U.S. investors, such volatility underscores the event-driven nature of development-stage biopharmaceutical stocks, where regulatory milestones, trial updates and financing decisions can exert a larger influence on share price trajectories than traditional valuation metrics based on stable earnings streams, as reflected in commentary from specialist platforms covering Spero and similar companies.GuruFocus as of 05/13/2026

Why Spero Therapeutics matters for US investors

Spero Therapeutics is listed on Nasdaq and based in Cambridge, Massachusetts, placing it squarely within the U.S. biotech ecosystem and making it accessible to a broad range of American retail and institutional investors through standard brokerage platforms and retirement accounts focused on U.S.-listed equities.

The company’s work on tebipenem HBr and other anti-infective programs also connects directly to the U.S. healthcare system, where antibiotic resistance and hospital resource constraints are ongoing concerns for payers, providers and public health agencies, giving the company’s pipeline potential relevance beyond purely financial considerations.Business Insider as of 05/13/2026

For investors who monitor the broader anti-infectives segment, Spero offers exposure to a partnership-driven model where large pharma collaborators such as GSK provide development and commercialization capabilities, while Spero retains economic participation through milestones and royalties, a structure that can concentrate risk and reward around specific programs and regulatory events.

Conclusion

Spero Therapeutics enters mid-2026 with first-quarter results showing lower revenue tied to reduced clinical activity but with a significant regulatory catalyst approaching in the form of the June 18, 2026 FDA decision on tebipenem HBr, which is being developed with GSK for complicated urinary tract infections, according to recent company disclosures and partner updates. The outcome of this review could reshape Spero’s financial profile through milestone payments and potential future royalties while also influencing sentiment toward its broader anti-infective pipeline. At the same time, the company’s small-cap status and reliance on a limited number of late-stage programs mean that its Nasdaq-listed shares may remain volatile as U.S. investors weigh regulatory risk, funding needs and the evolving commercial landscape for novel antibiotics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.